Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Daily News

Low Diastolic Blood Pressure Linked to Subclinical Myocardial Damage and Coronary Events: ARIC Analysis

Michael O'Riordan

October 06, 2016

News Features

Sodium Wars: Where Some See Linear Link With All-Cause Death, Others See No Need to Change Western Ways

Michael O'Riordan

October 05, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Daily News

ADVANCE结果发布：卒中发生率随着TAVR的进步而降低

Yael L. Maxwell

July 15, 2015

News Daily News

ADVANCE Published: Stroke Rate Diminishing as TAVR Evolves

Yael L. Maxwell

July 15, 2015

News Daily News

ADVANCE Publicado: el Índice de ACV Disminuye a Medida que Evoluciona la TAVR

Yael L. Maxwell

July 15, 2015

Presentation

Incidence and Predictors of Early and Midterm Clinically Relevant Neurological Events After TAVR

Presenter: Johan Bosmans

July 14, 2015

News Daily News

CLOSURE I Analysis Suggests Many Recurrent Strokes Are Unrelated to PFO

August 20, 2014

Advertisement

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Low Diastolic Blood Pressure Linked to Subclinical Myocardial Damage and Coronary Events: ARIC Analysis

Sodium Wars: Where Some See Linear Link With All-Cause Death, Others See No Need to Change Western Ways

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

ADVANCE结果发布：卒中发生率随着TAVR的进步而降低

ADVANCE Published: Stroke Rate Diminishing as TAVR Evolves

ADVANCE Publicado: el Índice de ACV Disminuye a Medida que Evoluciona la TAVR

Incidence and Predictors of Early and Midterm Clinically Relevant Neurological Events After TAVR

CLOSURE I Analysis Suggests Many Recurrent Strokes Are Unrelated to PFO

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content